Acute myeloid leukemia (AML) represents a group of clonal hematopoietic stem cell disorders which fail to differentiate and proliferate result in the accumulation of nonfunctional myeloblasts. In AML, response of patients to therapy is variables and there is no reliable marker to predict treatment response or prognosis of the disease. In this study, the main objective was to determine proteomic profiles of AML in patients referred to the King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia. The AML patients were categorized according to risk degree based on the probability of survival. Clinical data were collected from 22 patients (16 males and 6 females) with consent. A clinical data form was developed to collect infor...
Acute myeloid leukemia (AML) is an aggressive hematological malignancy. Nearly 50% of the patients w...
With the current reproducibility of proteome preparation workflows along with the speed and sensitiv...
Acute myeloid leukaemia (AML) is a heterogeneous disease characterised by clonal malignant haematopo...
Acute myeloid leukemia (AML) represents a group of clonal hematopoietic stem cell disorders which fa...
Because protein function regulates the phenotypic characteristics of cancer, a functional proteomic ...
Acute myeloid leukemia (AML) is characterized by an increasing number of clonal myeloid blast cells...
Acute myeloid leukemia (AML) is characterized by an increasing number of clonal myeloid blast cells...
Acute myeloid leukemia (AML) is characterized by an increasing number of clonal myeloid blast cells ...
Acute myeloid leukemia (AML) is characterized by an increasing number of clonal myeloid blast cells ...
Acute myeloid leukemia (AML) is an extremely heterogeneous and deadly hematological cancer. Cytogene...
Proteome analysis is a complex and dynamic process that encompasses several analytical platforms tha...
Acute myeloid leukemia (AML) is an aggressive blood cancer with a poor prognosis. We report a compre...
Acute myeloid leukemia (AML) is an aggressive blood cancer with a poor prognosis. We report a compre...
Introduction: The biological heterogeneity of acute myeloid leukemia (AML) complicates personalized ...
During the last decade, several large clinical studies have demonstrated that analysis of chromosoma...
Acute myeloid leukemia (AML) is an aggressive hematological malignancy. Nearly 50% of the patients w...
With the current reproducibility of proteome preparation workflows along with the speed and sensitiv...
Acute myeloid leukaemia (AML) is a heterogeneous disease characterised by clonal malignant haematopo...
Acute myeloid leukemia (AML) represents a group of clonal hematopoietic stem cell disorders which fa...
Because protein function regulates the phenotypic characteristics of cancer, a functional proteomic ...
Acute myeloid leukemia (AML) is characterized by an increasing number of clonal myeloid blast cells...
Acute myeloid leukemia (AML) is characterized by an increasing number of clonal myeloid blast cells...
Acute myeloid leukemia (AML) is characterized by an increasing number of clonal myeloid blast cells ...
Acute myeloid leukemia (AML) is characterized by an increasing number of clonal myeloid blast cells ...
Acute myeloid leukemia (AML) is an extremely heterogeneous and deadly hematological cancer. Cytogene...
Proteome analysis is a complex and dynamic process that encompasses several analytical platforms tha...
Acute myeloid leukemia (AML) is an aggressive blood cancer with a poor prognosis. We report a compre...
Acute myeloid leukemia (AML) is an aggressive blood cancer with a poor prognosis. We report a compre...
Introduction: The biological heterogeneity of acute myeloid leukemia (AML) complicates personalized ...
During the last decade, several large clinical studies have demonstrated that analysis of chromosoma...
Acute myeloid leukemia (AML) is an aggressive hematological malignancy. Nearly 50% of the patients w...
With the current reproducibility of proteome preparation workflows along with the speed and sensitiv...
Acute myeloid leukaemia (AML) is a heterogeneous disease characterised by clonal malignant haematopo...